Early-stage investors have been among the biggest backers of health tech companies focused on women’s health conditions, CNBC reports. Venture capital funding for so-called Femtech has tripled since 2015 from just over $600 million to nearly $1.9 billion last year, according to Pitchbook data. Yet, analysts say overall investment in women’s health remains underfunded. Beyond breast cancer, female health conditions garnered just 1% of pharmaceutical research funding in 2020, according to a McKinsey report. Just 2% of medical tech funding was devoted to non-cancer related women’s conditions. Read more.
Related Posts
Healthcare Subsectors Drive Double-Digit M&A Decline in 2023
According to LevinPro HC, there have been 1,299 healthcare M&A deals this year through July 31. This represents a 12% drop compared to the year-ago period.
September 5, 2023
Rural Hospital Closures Expected to Pick Up as Relief Dollars Go Away
The nonprofit Chartis Group released a study that found nearly 51% of rural hospitals have a negative operating margin, and the number of facilities eliminating services like obstetrics increased in 2022.
February 9, 2023
Health Tech Investors are Getting Selective, Expecting Slow Growth, Consolidation
As customers — often health systems, payers, or employers — and backers plot how they’ll invest shrinking budgets, they’re increasingly savvy about metric
October 25, 2023
Why General Catalyst Is Doubling Down on Health Care Investments
Roughly a year after closing its first $600 million health care fund, the firm last month launched its $670 million Health Assurance Fund II, focusing on health system partnerships.
August 26, 2022